Interrelationship between sleep-disordered breathing and sarcoidosis

Chest

Volumn 148, Issue 4, 2015, Pages 1105-1114

  Lal, Chitra ^a   Medarov, Boris I ^b   Judson, Marc A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIAL GAS; ARTICLE; CONCEPTUAL FRAMEWORK; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; HUMAN; MANAGED CARE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SARCOIDOSIS; SLEEP DISORDERED BREATHING; COMPLICATION; POLYSOMNOGRAPHY; PSYCHOLOGY; QUALITY OF LIFE; SLEEP APNEA SYNDROMES;

HUMANS; POLYSOMNOGRAPHY; QUALITY OF LIFE; SARCOIDOSIS; SLEEP APNEA SYNDROMES;

EID: 84943413662     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0584     Document Type: Article

References (72)

1. Verbraecken J, Hoitsma E, van der Grinten CP, Cobben NA, Wouters EF, Drent M. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21 (2): 137-146.
2. Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997; 14 (1): 61-64.
3. Pihtili A, Bingol Z, Kiyan E, Cuhadaroglu C, Issever H, Gulbaran Z. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath. 2013; 17 (4): 1281-1288.
4. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993; 328 (17): 1230-1235.
5. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013; 177 (9): 1006-1014.
6. Patterson KC, Huang F, Oldham JM, Bhardwaj N, Hogarth DK, Mokhlesi B. Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis. Chest. 2013; 143 (6): 1562-1568.
7. Bingol Z, Pihtili A, Gulbaran Z, Kiyan E. Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis. Clin Respir J. 2015; 9 (1): 14-21.
8. Panselinas E, Halstead L, Schlosser RJ, Judson MA. Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J. 2010; 103 (9): 870-875.
9. Ahmed M, Sulaiman I, Rutherford R, Gilmartin JJ. First presentation of sarcoidosis with severe obstructive sleep apnoea and epiglottic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30 (2): 146-148.
10. James DG, Barter S, Jash D, MacKinnon DM, Carstairs LS. Sarcoidosis of the upper respiratory tract (SURT). J Laryngol Otol. 1982; 96 (8): 711-718.
11. Sériès F, Cormier Y, Lampron N, La Forge J. Increasing the functional residual capacity may reverse obstructive sleep apnea. Sleep. 1988; 11 (4): 349-353.
12. Tohda S, Akagawa S, Miura Y, et al. A case of sarcoidosis associated with diabetes insipidus, anterior pituitary insufficiency and alveolar hypoventilation on a central basis [in Japanese]. Nihon Naika Gakkai Zasshi. 1989; 78 (3): 374-378.
13. Tomita Y, Kasai T, Kisaka T, et al. Altered breathing syndrome in heart failure: newer insights and treatment options. Curr Heart Fail Rep. 2015; 12 (2): 158-165.
14. Kim H, Bach JR. Central alveolar hypoventilation in neurosarcoidosis. Arch Phys Med Rehabil. 1998; 79 (11): 1467-1468.
15. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000; 118 (2): 372-379.
16. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012; 40 (1): 255-263.
17. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008; 133 (5): 1189-1195.
18. Kalkanis A, Yucel RM, Judson MA. The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30 (1): 60-64.
19. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res. 2003; 54 (4): 345-352.
20. Medarov BI, Victorson DE, Judson MA. Patient-reported outcome measures for sleep disorders and related problems: clinical and research applications. Chest. 2013; 143 (6): 1809-1818.
21. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002; 165 (9): 1217-1239.
22. Wisskirchen T, Teschler H. Central sleep apnea syndrome and Cheyne-Stokes respiration [in German]. Ther Umsch. 2000; 57 (7): 458-462.
23. Fleischer M, Hinz A, Brähler E, Wirtz H, Bosse-Henck A. Factors associated with fatigue in sarcoidosis. Respir Care. 2014; 59 (7): 1086-1094.
24. de Kleijn WP, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013; 18 (2): 439-452.
25. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001; 163 (2): 329-334.
26. de Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009; 15 (5): 499-506.
27. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22 (3): 235.
28. Balachandran JS, Masa JF, Mokhlesi B. Obesity hypoventilation syndrome epidemiology and diagnosis. Sleep Med Clin. 2014; 9 (3): 341-347.
29. Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. The use of health-care resources in obesity-hypoventilation syndrome. Chest. 2001; 120 (2): 377-383.
30. Piper AJ. Obesity hypoventilation syndrome-the big and the breathless. Sleep Med Rev. 2011; 15 (2): 79-89.
31. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013; 10 (4): 362-370.
32. Brådvik I, Wollmer P, Blom-Bülow B, Albrechtsson U, Jonson B. Lung mechanics and gas exchange during exercise in pulmonary sarcoidosis. Chest. 1991; 99 (3): 572-578.
33. Akkoca O, Celik G, Ulger F, et al. Exercise capacity in sarcoidosis. Study of 29 patients. Med Clin (Barc). 2005; 124 (18): 686-689.
34. Fagan KA. Selected contribution: pulmonary hypertension in mice following intermittent hypoxia. J Appl Physiol (1985). 2001; 90 (6): 2502-2507.
35. McGuire M, Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J. 2001; 18 (2): 279-285.
36. Sun X, Luo J, Xiao Y. Continuous positive airway pressure is associated with a decrease in pulmonary artery pressure in patients with obstructive sleep apnoea: a meta-analysis. Respirology. 2014; 19 (5): 670-674.
37. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006; 61 (1): 68-74.
38. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006; 129 (5): 1246-1252.
39. Westcott JL, DeGraffAC Jr. Sarcoidosis, hilar adenopathy, and pulmonary artery narrowing. Radiology. 1973; 108 (3): 585-586.
40. Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med. 1977; 101 (4): 170-174.
41. Takemura T, Matsui Y, Oritsu M, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol. 1991; 418 (4): 361-368.
42. Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011; 140 (5): 1261-1266.
43. Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest. 1989; 96 (4): 729-737.
44. Podszus T, Bauer W, Mayer J, Penzel T, Peter JH, von Wichert P. Sleep apnea and pulmonary hypertension. Klin Wochenschr. 1986; 64 (3): 131-134.
45. Weitzenblum E, Krieger J, Apprill M, et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis. 1988; 138 (2): 345-349.
46. Sanner BM, Doberauer C, Konermann M, Sturm A, Zidek W. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med. 1997; 157 (21): 2483-2487.
47. Arias MA, Garcîa-Rîo F, Alonso-Fernández A, Martînez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J. 2006; 27 (9): 1106-1113.
48. Sajkov D, Wang T, Saunders NA, Bune AJ, Neill AM, Douglas Mcevoy R. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am J Respir Crit Care Med. 1999; 159 (5 pt 1): 1518-1526.
49. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest. 1996; 109 (2): 380-386.
50. Laks L, LehrhaftB, Grunstein RR, Sullivan CE. Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J. 1995; 8 (4): 537-541.
51. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax. 2000; 55 (11): 934-939.
52. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008; 32 (2): 296-302.
53. Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med. 2010; 5(2): 86-91.
54. Maimon N, Salz L, Shershevsky Y, Matveychuk A, Guber A, Shitrit D. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis. 2013; 17 (3): 406-411.
55. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005; 128 (3): 1483-1489.
56. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosisassociated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010; 138 (5): 1078-1085.
57. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005; 25 (5): 783-788.
58. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008; 27 (3): 329-334.
59. Milman N, Svendsen CB, Iversen M, Videbaek R, Carlsen J. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J. 2009; 3 (4): 207-213.
60. Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28 (2): 139-145.
61. Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014; 145 (4): 810-817.
62. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009; 26 (2): 110-120.
63. Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006; 23 (2): 108-116.
64. Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol. 2013; 111 (2): 278-285.
65. Moser NJ, Phillips BA, Guthrie G, Barnett G. Effects of dexamethasone on sleep. Pharmacol Toxicol. 1996; 79 (2): 100-102.
66. Li Y, Panossian LA, Zhang J, et al. Effects of chronic sleep fragmentation on wake-active neurons and the hypercapnic arousal response. Sleep. 2014; 37 (1): 51-64.
67. Baughman RP, Lower EE, Tami T. Upper airway. 4: sarcoidosis of the upper respiratory tract (SURT). Thorax. 2010; 65 (2): 181-186.
68. Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore). 2006; 85 (6): 365-371.
69. Zeitlin JF, Tami TA, Baughman R, Winget D. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol. 2000; 14 (3): 157-161.
70. Kay DJ, Har-El G. The role of endoscopic sinus surgery in chronic sinonasal sarcoidosis. Am J Rhinol. 2001; 15 (4): 249-254.
71. Salari M, Rezaieyazdi Z. Prevalence and clinical picture of musculoskeletal sarcoidosis. Iran Red Crescent Med J. 2014; 16 (7): e17918.
72. Nozaki K, Judson MA. Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Med. 2012; 41 (6 pt 2): e331-e348.